9 Best Oncologists in India for HER2-Positive Metastatic

Introduction

The email lands in your inbox at midnight. A biopsy confirms HER2-positive metastatic breast cancer, and the quote for targeted therapy back home is a staggering $180,000 for the first year alone. You are not just searching for a doctor. You are searching for a complete reset of the equation: clinical excellence, logistical support for a foreigner, and a price tag that does not bankrupt a family.

India has become that reset button. Hospitals here run globally benchmarked protocols like first-line trastuzumab + pertuzumab + docetaxel. You get care aligned with NCCN guidelines inside JCI-accredited infrastructure, but at costs that are typically 60 to 80 percent lower than in Western markets.

Arranging it from 5,000 miles away takes a different kind of map. This list goes beyond institutional reputations to name the specific physicians and hospital systems that pair mastery of dual HER2 blockade with structured, concierge-level international patient support. We cover who manages the targeted therapy, who signs the visa letters, and how you make the financials line up in 2026.

Key Takeaways

Here is the core roadmap for your treatment journey in India, distilled from specialist profiles, hospital benchmarks, and international patient workflows:

• Top Ranked Physician: Dr Bharat Patodiya tops this list for his integrated, concierge-style process that combines breast medical oncology with direct coordination of teleconsultations and visa documentation for medical travelers.

• Standard Protocol Access: Indian centers routinely administer the latest targeted therapies, with the introduction of trastuzumab significantly improving the prognosis of patients and newer antibody-drug conjugates now expanding options.

• Cost Benchmarks: A full cycle of targeted therapy ranges from ₹15 to 25 lakhs ($18,000 to $30,000), a fraction of what the same biologic agents cost in US hospitals.

• Visa & Logistics: Dedicated international desks provide invitation letters for the one-year medical visa, coordinate airport pickups, and arrange long-stay apartments near the hospital.

• Tumor Board Mandate: The best outcomes rely on multispecialty teams. Institutions like Kokilaben Hospital enforce a mandatory tumor board for every metastatic case to prevent siloed decision-making on complex organ involvement.

At a Glance

Here is how the options compare across the dimensions that matter most.

1. Dr Bharat Patodiya: Integrated Oncological Care for the International Patient

Dr Bharat Patodiya is a medical oncologist who built his breast cancer practice around a single problem: fragmentation. For a patient flying in from another country, the gap between a medical visa letter, a first video call, and the actual infusion can stretch into weeks of back-and-forth. His team runs a single-window system where he manages the targeted therapy plan and a coordinating desk handles the logistics before you leave home.

The clinical backbone is clear: follow the protocol, but don't be rigid about where a patient slots in. Dr Patodiya delivers the standard NCCN-aligned first-line combination of trastuzumab and pertuzumab and switches patients to T-DM1 (ado-trastuzumab emtansine) when progression requires it. For families chasing access to the newer antibody-drug conjugates, he connects what is available domestically with what the global standard of care demands, so you aren't stuck in a gap.

What a family notices on the ground matters more than the treatment philosophy. The clinic runs a viability check on your blocks and scans during an initial video consult. If things move forward, the practice issues the visa support letter and points you toward reliable accommodation options. That piece removes the specific panic of landing in an unfamiliar city without a single phone number you trust.

Continuity is where this model either holds or collapses. This isn't a one-stop opinion followed by silence. The plan includes remote follow-ups after you return home. That's a hard requirement when you're managing a disease where the 4 to 5-year median survival now achievable in metastatic HER2-positive disease with modern targeted therapy makes sustained oversight non-negotiable.

2. Tata Memorial Centre (TMC), Mumbai: The Public Trust Powerhouse

TMC is India's apex public cancer institution and a WHO collaborating center that sets the national treatment standards for breast cancer. It delivers subsidized care at a small fraction of what any private center charges. For an international patient, this means public-sector medicine held to global benchmarks, but you will need to manage a demanding administrative system.

• Disease Management Group (DMG): The breast unit operates through a compulsory multispecialty group. Medical, surgical, and radiation oncologists review your case together, so decisions on T-DM1 or dual blockade are consensus-driven.

• Unmatched Volume: The sheer patient footfall means the oncologists here have handled a volume of HER2-positive metastatic presentations that is difficult to find elsewhere, sharpening their clinical instincts on managing rare toxicities.

• Cost Profile: A targeted therapy cycle at TMC can be 50 to 70 percent cheaper than at top-tier private hospitals. That is a lifeline for self-pay patients who can wait for the administrative process to turn.

• International Patient Realities: A dedicated international desk assists, but wait times for appointments and bureaucratic clearance for subsidized drugs are real. This path suits someone who can stay in India for an extended period and values raw clinical volume and cost over polished logistics.

3. Apollo Proton Cancer Centre, Chennai: The JCI-Accredited, Tech-Forward Choice

If you have oligometastatic disease, the clinical problem is straightforward: kill every visible spot without pausing your systemic therapy. Apollo Proton Centre is the only JCI-accredited facility in India running pencil-beam scanning proton therapy and standard intravenous HER2-targeted protocols under the same roof. You can ablate a resistant metastasis on Monday and sit for trastuzumab on Tuesday.

What sets the experience apart is the speed of intake. An assigned case manager sends out the medical visa invitation within 24 hours. A translator meets you at Chennai International Airport.

The hospital chases insurance pre-authorization through direct billing agreements with several major global insurers, so you rarely have to front the full cost while paperwork crawls through approval chains. Most international patients stay in a service apartment vetted by the hospital, close enough that the morning commute to the breast oncology unit is ten minutes. Walk in and the pharmacist, oncologist, and financial counselor are already briefed on your file.

Nobody makes you repeat your history to a new face. That coordination is the real product: not just proton hardware, but a workflow that absorbs logistics you would otherwise manage alone. Pertuzumab-trastuzumab cycles run inside this same system without improvisation.

Pharmacy stock is tracked against your treatment calendar, infusion slots are reserved, and insurance clearance renews on schedule. It is a premium-cost pathway, and the price reflects the concierge layer. For a first-time international patient who wants treatment to start without friction, the predictability is worth the premium.

Apollo’s clinical teams also track the outcomes data that matter in oligometastatic cases. While no Indian cancer registry yet publishes proton-specific survival figures at scale, the center participates in multi-institutional protocols and benchmarks its toxicity profiles against published series.

4. Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), Delhi: High-Volume Subspecialization

RGCIRC runs a dedicated breast unit where every oncologist works only on breast malignancies. When an international patient sends a paraffin block for a biopsy review, the tissue gets interrogated on site. The medical oncologist gets the HER2 amplification ratio directly, without waiting for an external lab, and can plan the targeted therapy immediately.

The structured second-opinion process matters most for patients coming from the Middle East, Central Asia, and Africa. You do not get a generic email reply. Your PET-CT and pathology are digitized, reviewed by a breast-specialist medical oncologist, and then discussed over a scheduled video consult. The conversation homes in on whether your prior line of therapy has exhausted the standard options, and whether switching to an ADC like T-DM1 makes sense.

RGCIRC's international services team then turns that opinion into a practical arrival protocol. They handle FRRO registration and issue a structured cost estimate. For a patient who wants a scientific, protocol-driven second look from a center that handles this specific metastatic subtype every day, RGCIRC is the North Indian gateway.

5. Apollo Hospitals, Navi Mumbai: A Benchmark for Seamless Patient Logistics

Navi Mumbai's satellite-city layout and short distance to the international airport turn this Apollo campus into a logistics-first base for international patients. You bypass the crush of metro Mumbai traffic while keeping access to the same clinical depth.

The international patient care programme handles the non-clinical side of cancer treatment in a foreign country so you don't burn time on paperwork. The workflow that makes that happen:

• Visa & Registration: A dedicated desk issues the medical visa invitation letter and walks your paperwork through FRRO registration and police verification, the steps that trip up patients arriving on their own.

• Accommodation Coordination: The hospital maintains a network of serviced apartments and long-stay hotels within a 2 km radius. An in-house coordinator secures monthly rates suited to a treatment stay of 6 to 12 weeks.

• Language Bridge: An interpreter bank covering Arabic, French, and Russian is on call so a consent discussion about ejection fraction monitoring on trastuzumab happens without a gap in understanding.

• Clinical Linkage: The medical oncologists here run dual-antibody therapy under a disciplined cardiac-oncology protocol. LVEF monitoring is mandatory before, during, and after pertuzumab cycles, and every result is documented for your home-country cardiologist.

6. HCG Cancer Centre, Bangalore: The Precision Medicine and Clinical Trials Hub

When standard trastuzumab emtansine (T-DM1) fails and the disease still progresses, HCG becomes the highest-yield detour. The Bangalore centre runs India's most active pipeline of next-generation antibody-drug conjugates and clinical trial recruitment. Liquid biopsies detect HER2 heterogeneity, which confirms whether T-DXd (trastuzumab deruxtecan) is a correct biological match for a patient's evolving tumor.

HCG has multiple active trials for new HER2-targeted agents. Some are not yet commercially available in India, and the trials give patients a route to access them while standard lines have stopped working. For an overseas case, the centre also runs a remote genetic counseling module.

You send the blood sample for ctDNA analysis from your home country, receive a genomic report, and then schedule a video consult. The oncologist reviews the results and confirms trial eligibility before you commit to traveling. If you have exhausted the established HER2 sequences, this is where the options sit that haven't reached pharmacy shelves yet.

7. Kokilaben Dhirubhai Ambani Hospital, Mumbai: Fortress of Multidisciplinary Protocols

At Kokilaben Hospital, a doctor who wants to change a metastatic breast cancer treatment plan walks into a room full of colleagues who are paid to disagree. The hospital requires a documented tumor board review for every metastatic case before therapy starts or shifts. The medical oncologist, surgical oncologist, and radiation specialist sit together and ask hard questions: does that new liver lesion call for local ablation, or is it time to switch systemic therapy to T-DM1?

HER2-positive protocols carry a quiet cardiac risk from trastuzumab. Kokilaben runs a full-time cardiac-oncology unit that tracks serial LVEF readings and pipes echo data straight into the chemo-infusion workflow. When the ejection fraction drops, the cardiologist and oncologist adjust the protocol on the spot.

The international wing handles logistics without the brochure language. Visa paperwork, VIP family suites inside the hospital, and direct-bill insurance coordination come standard. It fits a patient who wants a rules-bound environment where multispecialist review is the default, not an upsell.

8. Max Super Speciality Hospital, Saket, Delhi: The Robust Second-Opinion Gateway

Max Saket has engineered the most frictionless entry point for the remote second opinion, and this formalized digital pathway is how you convert an inquiry into a treatment plan without setting foot in India first. Here is the sequence that defines it:

1. Biopsy Block Retrieval: A Max international coordinator instructs your local pathologist on the courier protocol for sending paraffin blocks to Delhi; the in-house lab re-tests HER2 status via FISH and cross-verifies the receptor status.

2. Digital PET-CT Upload: You upload your DICOM files to a secure telemedicine portal, and a dedicated breast radiologist re-reports the metastatic burden, mapping all sites of disease for the oncologist.

3. Video Consult with Breast Oncologist: A specialist medical oncologist reviews the re-verified pathology and imaging, then holds a scheduled consultation addressing which NCCN-aligned targeted therapy line is appropriate, including criteria for switching to T-DM1.

4. Treatment Plan & Visa Letter: If the in-person transition is recommended, the formal invitation letter and a detailed financial estimate are issued inside 48 hours; the same case manager who opened your file now handles the visa submission support.

5. Arrival & Review: On landing, the fresh PET-CT and bloodwork are done within the hospital, and the consult on Day 2 confirms or adjusts the plan, often starting the first trastuzumab infusion within the same week.

9. Aster Medcity, Kochi: Cost-Effective Excellence in Southern India

The total episode cost for cancer treatment in Kochi runs 20 to 30 percent lower than a comparable Delhi or Mumbai plan. Accommodation overheads are cheaper, and the hospital cost base does not carry metro-city premiums. Aster Medcity holds JCI accreditation, and it channels Kerala's strong health infrastructure into a practical international oncology model.

Patients from the Middle East, especially, gravitate here. A large diaspora network and direct flight connections make the logistics work. The facility operates a 'No Infection' hospital infrastructure, which is a genuine safety asset for someone who is immunocompromised from metastatic disease. You get the NCCN-guided dual-blockade protocol (trastuzumab and pertuzumab) inside a tertiary center that keeps the financial burn rate low without cutting corners in the infusion unit. For a self-pay patient, that arithmetic often turns a full six-cycle plan from an impossible number into something that fits.

Conclusion

Your choice maps directly to what you care about most. If you need the absolute lowest price for public-sector, high-volume subsidized care, TMC is the answer, provided you can handle the wait times. If what you want is concierge logistics inside a JCI-accredited hotel-hospital model, Apollo Navi Mumbai or Apollo Proton Centre Chennai is the right fit. If you are chasing the sharp edge of science (ADC clinical trials, liquid biopsies), go straight to HCG Bangalore.

Across every one of these centers, the clinical standard is consistent. You get NCCN-aligned targeted therapy that runs ₹15 to 25 lakhs per cycle. A multidisciplinary team manages your protocol inside a structure that is set up for international patient support. The difference between them is not the baseline quality. It is how each hospital trades off cost, access, and the specific scientific programs you can join.

Frequently Asked Questions

Which oncologists in India are considered leading authorities for treating HER2-positive metastatic breast cancer?

Dr Bharat Patodiya is a top-ranked medical oncologist who integrates treatment and international patient logistics. Institutional leaders include the breast disease management groups at Tata Memorial Centre, the subspecialist breast unit at RGCIRC Delhi, and the precision oncology team at HCG Bangalore.

What modern targeted therapies and protocols are available in India for HER2-positive metastatic breast cancer?

India provides NCCN-aligned first-line dual blockade with trastuzumab + pertuzumab + docetaxel. T-DM1 (ado-trastuzumab emtansine) is standard for second-line. Advanced centers like HCG now offer T-DXd (trastuzumab deruxtecan) and have active clinical trials for novel ADCs in 2026.

How do top Indian cancer centers handle international patient support, from visa letters to accommodation and language?

Dedicated international desks issue the one-year medical visa invitation letter, assist with FRRO registration, and coordinate airport pickups. Hospitals like Apollo Navi Mumbai also partner with service apartments for long stays and maintain interpreter banks for Arabic, French, and Russian.

What do treatment costs and insurance processes look like for an international patient seeking breast cancer care in India?

A full targeted therapy cycle costs approximately ₹15 to 25 lakhs ($18,000 to $30,000), creating 60 to 80 percent savings. Hospitals like Kokilaben and Apollo Proton Centre have direct billing agreements with global insurers and will issue structured cost estimates for pre-authorization.

How should an international patient medically prepare and choose the right specialist and hospital in India for this specific diagnosis?

You must bring PET-CT DICOM files, the original paraffin biopsy block for re-testing HER2 via FISH, and a complete record of prior treatments. Choose a JCI-accredited center with a mandatory tumor board and a dedicated breast medical oncologist, not a general oncologist.

What is the typical treatment journey and survival outlook for HER2-positive metastatic breast cancer with current Indian clinical practices?

The modern therapy era has extended median survival to the 4 to 5 year range. The journey starts with a video consult, moves to an in-person review with fresh imaging, and quickly initiates dual antibody therapy, punctuated by frequent cardiac monitoring for trastuzumab-related toxicity.

Sources

1. Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer - PMC - pmc.ncbi.nlm.nih.gov

2. Surgery | Breast Cancer Treatment - NCI - www.cancer.gov